Innate Pharma (IPHYF) Non-Current Deffered Revenue (2017 - 2024)

Innate Pharma's Non-Current Deffered Revenue history spans 8 years, with the latest figure at $3.0 million for Q4 2024.

  • For Q4 2024, Non-Current Deffered Revenue fell 39.24% year-over-year to $3.0 million; the TTM value through Dec 2024 reached $3.0 million, down 39.24%, while the annual FY2024 figure was $3.1 million, 38.46% down from the prior year.
  • Non-Current Deffered Revenue reached $3.0 million in Q4 2024 per IPHYF's latest filing, down from $5.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $39.0 million in Q4 2020 to a low of $3.0 million in Q4 2024.
  • Average Non-Current Deffered Revenue over 5 years is $16.8 million, with a median of $8.1 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: dropped 12.76% in 2020, then crashed 72.2% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $39.0 million in 2020, then dropped by 25.37% to $29.1 million in 2021, then plummeted by 72.2% to $8.1 million in 2022, then plummeted by 38.52% to $5.0 million in 2023, then tumbled by 39.24% to $3.0 million in 2024.
  • Per Business Quant, the three most recent readings for IPHYF's Non-Current Deffered Revenue are $3.0 million (Q4 2024), $5.0 million (Q4 2023), and $8.1 million (Q4 2022).